Ku Chao-Yue, Yang Xue-Ke, Xi Li-Jing, Wang Rui-Zhe, Wu Bin-Bin, Dai Man, Liu Li, Ping Zhi-Guang
Department of Health Statistics, College of Public Health, Zhengzhou University, No. 100 Science Avenue, Zhengzhou, 450001, Henan Province, People's Republic of China.
School of Basic Medical Sciences, Zhengzhou University, No.100 Science Avenue, Zhengzhou, 450001, Henan Province, People's Republic of China.
J Cancer Res Clin Oncol. 2023 Sep;149(12):9927-9935. doi: 10.1007/s00432-023-04915-8. Epub 2023 May 30.
In cohort studies on liver cancer, there are often immortal time bias and interference of competing risk events. This study proposes to explore the role of internal and external radiotherapy for hepatocellular carcinoma using SEER data, using a competing risk model and controlling immortal time bias.
Data of SEER from 2004 till 2015 was included. To analyze whether there was a difference in survival between HCC (hepatocellular carcinoma) patients receiving external radiation and internal radiation, we used a competing risk analysis after excluding immortal time bias, and created a nomogram to assess the risk of cancer-specific death (CSD) in hepatocellular carcinoma patients receiving radiotherapy.
Potential confounding factors adjusted, there was no significant difference in CSD between external and internal radiation therapy [HR and its 95% CI = 1.098 (0.874-1.380)]. The constructed nomogram performed better than the traditional AJCC model. The AUC and calibration curve results showed that this well-calibrated nomogram could be used to make clinical decisions regarding the prognosis and personalized treatment of hepatocellular carcinoma treated. There was no difference in the cumulative risk of death between patients with liver cancer treated with external radiation therapy and internal radiation therapy.
There is no difference in the cumulative risk of death between patients with liver cancer treated with external radiation therapy and internal radiation therapy. The nomogram predicts the results more accurately. These results can be used to guide the choice of treatment options for patients with HCC and to predict their survival prognosis.
在肝癌队列研究中,常存在不朽时间偏倚和竞争风险事件的干扰。本研究建议利用监测、流行病学与结果(SEER)数据,采用竞争风险模型并控制不朽时间偏倚,探讨内、外放疗在肝细胞癌治疗中的作用。
纳入2004年至2015年的SEER数据。为分析接受外照射和内照射的肝细胞癌(HCC)患者的生存是否存在差异,我们在排除不朽时间偏倚后进行了竞争风险分析,并创建了列线图以评估接受放疗的肝细胞癌患者的癌症特异性死亡(CSD)风险。
在调整潜在混杂因素后,外照射和内照射治疗的CSD无显著差异[风险比(HR)及其95%置信区间(CI)=1.098(0.874 - 1.380)]。构建的列线图比传统的美国癌症联合委员会(AJCC)模型表现更好。曲线下面积(AUC)和校准曲线结果表明,这个校准良好的列线图可用于对接受治疗的肝细胞癌患者的预后和个体化治疗做出临床决策。接受外照射治疗和内照射治疗的肝癌患者的累积死亡风险没有差异。
接受外照射治疗和内照射治疗的肝癌患者的累积死亡风险没有差异。列线图能更准确地预测结果。这些结果可用于指导肝细胞癌患者治疗方案的选择并预测其生存预后。